24 research outputs found

    An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity

    Get PDF
    Macrophage migration inhibitory factor (MIF) is a major proinflammatory cytokine that has been increasingly implicated in the pathogenesis of several inflammatory, autoimmune, infectious and oncogenic diseases. Accumulating evidence suggests that the tautomerase activity of MIF plays a role in modulating some of its intra- and extra-cellular activities. Therefore, the identification and development of small-molecule inhibitors targeting the catalytic activity of MIF has emerged as an attractive and viable therapeutic strategy to attenuate its function in health and disease. Herein we report a novel virtual screening protocol for the discovery of new inhibitors of MIF's tautomerase activity. Our protocol takes into account the flexibility and dynamics of the catalytic site by coupling molecular dynamics (MD) simulations aimed at modeling the protein's flexibility in solution to (i) docking with FlexX, or (ii) docking with FlexX and pharmacophoric filtering with Unity. In addition, we applied in parallel a standalone docking using the new version of Surflex software. The three approaches were used to screen the ChemBridge chemical library and the inhibitory activity of the top-ranked 333 compound obtained from each approach (1000 compound in total) was assessed in vitro using the tautomerase assay. This biochemical validation process resulted in the identification of 12 novel MIF inhibitors corresponding to a 1.2% hit rate. Six of these hits came from Surflex docking; two from FlexX docking with MD simulations and four hits were identified with MDS and pharmacophore filtering with minimal overlap between the hits from each approach. Six hits were identified with IC50 values lower than 10 microM (three hits with IC50 lower than 1 microM); four were shown to be suicide inhibitors and act via covalent modification of the N-terminal catalytic residues Pro1. One additional inhibitor, N-phenyl-N-1,3,4-thiadiazol-2-yl-thiourea, (IC50=300 nM) was obtained from FlexX docking combined to pharmacophoric filtering on one of the eight MD structures. These results demonstrate the power of integrative in silico approaches in the discovery of new modulator of MIF's tautomerase activity. The chemical diversity and mode of action of these compounds suggest that they could be used as molecular probes to elucidate the functions and biology of MIF and as lead candidates in drug developments of anti-MIF drugs

    SH3 interactome conserves general function over specific form

    Get PDF
    Src homology 3 (SH3) domains bind peptides to mediate protein–protein interactions that assemble and regulate dynamic biological processes. We surveyed the repertoire of SH3 binding specificity using peptide phage display in a metazoan, the worm Caenorhabditis elegans, and discovered that it structurally mirrors that of the budding yeast Saccharomyces cerevisiae. We then mapped the worm SH3 interactome using stringent yeast two-hybrid and compared it with the equivalent map for yeast. We found that the worm SH3 interactome resembles the analogous yeast network because it is significantly enriched for proteins with roles in endocytosis. Nevertheless, orthologous SH3 domain-mediated interactions are highly rewired. Our results suggest a model of network evolution where general function of the SH3 domain network is conserved over its specific form

    Spécificité et inhibition des interactions protéine-protéine : Exemples d'approches

    No full text
    L’identification de molĂ©cules organiques capables de moduler des interactions protĂ©ine-protĂ©ine (PPIs) est longtemps restĂ©e un domaine peu exploitĂ© par la recherche pharmaceutique privĂ©e comme acadĂ©mique. Cependant, le dĂ©veloppement de mĂ©thodologies innovantes pour l’étude des PPIs et la validation rĂ©cente de ce type d’inhibiteurs dans des essais prĂ©cliniques, dĂ©montrent que les PPIs constituent une nouvelle source de cibles importantes. Les composĂ©s capables de moduler ces interactions reprĂ©sentent une nouvelle classe d’outils prometteurs, tant en recherche fondamentale qu’en thĂ©rapeutique. Elles peuvent aider Ă  diffĂ©rencier les multiples fonctions portĂ©es par une mĂȘme protĂ©ine, Ă  replacer la protĂ©ine dans une cascade de rĂ©actions, ainsi qu’à dissĂ©quer et reconstituer des rĂ©seaux de signalisations protĂ©iques. Ces molĂ©cules permettront Ă©galement de faire Ă©merger de nouvelles familles d’agents pharmacologiques actifs dans diverses pathologies.Mon travail de thĂšse s'est projetĂ© dans l'avenir de la recherche biomĂ©dicale, en ciblant les interactions protĂ©ine-protĂ©ine. J’ai pu durant mon doctorat mettre en Ɠuvre plusieurs mĂ©thodologies pour Ă©tudier et caractĂ©riser des interactions protĂ©iques afin de dĂ©velopper des inhibiteurs de ces interactions. J’ai ainsi pu travailler sur l’optimisation d’un composĂ© inhibiteur de l’interaction de la protĂ©ine virale Nef VIH-1 avec les domaines SH3 des Src kinases, le composĂ© DLC27. J’ai Ă©galement pu mettre en Ă©vidence la pertinence biologique de ce composĂ©, qui cible un mode d’interaction unique, ou trĂšs rare, au niveau cellulaire en Ă©tudiant l’interaction avec les domaines SH3 de deux protĂ©ines, ALIX (ALG2-Interacting Protein X) et la sous-unitĂ© p85 de la PI3K (phosphatidylinositol 3-kinase).J’ai Ă©galement pu caractĂ©riser la surface et le mode d’interaction de protĂ©ines virales impliquĂ©es dans le complexe de rĂ©plication du virus du SRAS (Syndrome Respiratoire Aigu SĂ©vĂšre). Cette Ă©tude tend Ă  montrer que la protĂ©ine virale nsp10 agit comme une plateforme de reconnaissance pour ses partenaires, les protĂ©ines virales nsp14 et nsp16. Ces interactions permettent l’activation ou l’augmentation des activitĂ©s respectives de nsp16 et nsp14 et jouent un rĂŽle au niveau de la rĂ©plication virale. Suite Ă  l’identification d’un ‘point chaud’ d’interaction, le rĂ©sidu Tyr96 Ă  la surface de nsp10, nous avons mis en Ă©vidence la premiĂšre famille de molĂ©cules inhibitrices du complexe nsp10-nsp14 en couplant des mĂ©thodes informatiques (in silico) Ă  des criblages expĂ©rimentaux. Ces molĂ©cules pourraient ĂȘtre utilisĂ©es comme antiviraux ou servir d’outils pour la recherche, en permettant par exemple de mieux comprendre et d’élucider les mĂ©canismes molĂ©culaires impliquĂ©s dans la rĂ©plication du virus du SRAS et des coronavirus en gĂ©nĂ©ral.Protein-protein interactions (PPIs) participate in and regulate almost all essential cellular functions. As a consequence, they are frequently involved in various pathologies (going from cancer development to viral replication and host cell infection) but their study remains a challenge.Thus understanding those interactions as well as finding small drug candidates able to modulate them, a field of research not currently fully developed, appear as the future of the healthcare industry.In this context, I chose to learn different techniques to study PPIs that are usually employed in academic (IMR laboratory, CNRS, France) or corporate environments (Genentech, USA). Moreover, I also worked on the development of small organic inhibitors of PPIs coupling in silico methodologies (chemo-informatics, Drug Design) to biological and structural validations.During my PhD, I could manage and work on different projects involving the study of PPIs involved in cancer signaling pathways as well as the development of potent antiviral drugs targeting the HIV and SARS viruses.My organizational, personal and scientific skills as well as the practical experience I developed on various techniques (from cell biology to biophysics, structural biochemistry and Drug Design), make me feel confident on the management of PPIs drug discovery projects.I am thus able to efficiently work on, and manage, the study of protein-protein interactions in various pathologies as well as the development of potent PPIs inhibitors, that will be a major breakthrough for Biotech/Pharma companies in the coming years

    Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALG-2-interacting protein X (Alix)

    Get PDF
    International audienceThe functions of Src family kinases are tightly regulated through Src homology (SH) domainmediated protein-protein interactions. We previously reported the biophysical characteristics of the apoptosis-linked gene 2-interacting protein X (Alix) in complex with the haemopoietic cell kinase (Hck) SH3 domain. In the current study, we have combined ITC, NMR, SAXS and molecular modeling to determine a 3D model of the complex. We demonstrate that Hck SH3 recognizes an extended linear proline-rich region of Alix. This particular binding mode enables Hck SH3 to sense a specific non-canonical residue situated in the SH3 RT-loop of the kinase. The resulting model helps clarify the mechanistic insights of Alix-Hck interaction

    A specific protein disorder catalyzer of HIV-1 Nef

    No full text
    International audienceThe HIV-1 auxiliary protein Nef is required for the onset and progression of AIDS in HIV-1-infected persons. Here, we have deciphered the mode of action of a second-generation inhibitor of Nef, DLC27-14, presenting a competitive IC50 o

    Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain and ALG-2-interacting protein X

    No full text
    International audienceSFKs (Src family kinases) are central regulators of many signaling pathways. Their functions are tighly regulated through SH ( Src homology) domain-mediated protein-protein interactions. A yeast two-hybrid screen using SH3 domains as bait identified Alix [ALG-2(apoptosis-linked gene 2)-interacting protein X] as a novel Hck (haemopoietic cell kinase) SH3 domain interactor. The Alix-Hck-SH3 interaction was confirmed in vitro by a GST (glutathione transferase) pull-down assay and in intact cells by a mammalian two-hybrid assay. Furthermore, the interaction was demonstrated to be biologically relevant in cells. Through biophysical experiments, we then identified the PRR (proline-rich region) motif of Alix that binds Hck-SH3 and determined a dissociation constant of 34.5”M. Heteronuclear NMR spectroscopy experiments were used to map the Hck-SH3 residues that interact with an ALIX construct containing the V and PRR domains or with the minimum identified interacting motif. Finally, SAXS (small-angle X-ray scattering) analysis showed that the terminal PRR of Alix is unfolded, at least before Hck-SH3 recognition. These results indicate that residues outside the canonical PxxP motif of Alix enhance its affinity and selectivity towards Hck-SH3. The structural framework of the HcK-Alix interaction will help to clarify how Hck and Alix assist during virus budding and cell-surface receptor regulatio

    Synergy and allostery in ligand binding by HIV-1 Nef

    No full text
    International audienceThe Nef protein of human and simian immunodeficiency viruses boosts viral pathogenicity through its interactions with host cell proteins. By combining the polyvalency of its large unstructured regions with the binding selectivity and strength of its folded core domain, Nef can associate with many different host cell proteins, thereby disrupting their functions. For example, the combination of a linear proline-rich motif and hydrophobic core domain surface allows Nef to bind tightly and specifically to SH3 domains of Src family kinases. We investigated whether the interplay between Nef's flexible regions and its core domain could allosterically influence ligand selection. We found that the flexible regions can associate with the core domain in different ways, producing distinct conformational states that alter the way in which Nef selects for SH3 domains and exposes some of its binding motifs. The ensuing crosstalk between ligands might promote functionally coherent Nef-bound protein ensembles by synergizing certain subsets of ligands while excluding others. We also combined proteomic and bioinformatics analyses to identify human proteins that select SH3 domains in the same way as Nef. We found that only 3% of clones from a whole-human fetal library displayed Nef-like SH3 selectivity. However, in most cases, this selectivity appears to be achieved by a canonical linear interaction rather than by a Nef-like 'tertiary' interaction. Our analysis supports the contention that Nef's mode of hijacking SH3 domains is a virus-specific adaptation with no or very few cellular counterparts. Thus, the Nef tertiary binding surface is a promising virus-specific drug target

    Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes

    Get PDF
    International audienceThe RNA-synthesizing machinery of the severe acute respiratory syndrome Coronavirus (SARS-CoV) is composed of 16 non-structural proteins (nsp1-16) encoded by ORF1a/1b. The 148-amino acid nsp10 subunit contains two zinc fingers and is known to interact with both nsp14 and nsp16, stimulating their respective 3'-5' exoribonuclease and 2'-O-methyltransferase activities. Using alanine-scanning mutagenesis, in cellulo bioluminescence resonance energy transfer experiments, and in vitro pulldown assays, we have now identified the key residues on the nsp10 surface that interact with nsp14. The functional consequences of mutations introduced at these positions were first evaluated biochemically by monitoring nsp14 exoribonuclease activity. Disruption of the nsp10-nsp14 interaction abrogated the nsp10-driven activation of the nsp14 exoribonuclease. We further showed that the nsp10 surface interacting with nsp14 overlaps with the surface involved in the nsp10-mediated activation of nsp16 2'-O-methyltransferase activity, suggesting that nsp10 is a major regulator of SARS-CoV replicase function. In line with this notion, reverse genetics experiments supported an essential role of the nsp10 surface that interacts with nsp14 in SARS-CoV replication, as several mutations that abolished the interaction in vitro yielded a replication-negative viral phenotype. In contrast, mutants in which the nsp10-nsp16 interaction was disturbed proved to be crippled but viable. These experiments imply that the nsp10 surface that interacts with nsp14 and nsp16 and possibly other subunits of the viral replication complex may be a target for the development of antiviral compounds against pathogenic coronaviruses

    Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

    No full text
    Masitinib is a protein kinase inhibitor that sensitises refractory pancreatic adenocarcinoma cells to treatment with the nucleoside analog gemcitabine. Here the authors show that Masitinib activates deoxycytidine kinase to enhance phosphorylation of nucleoside analogue pro-drugs, increasing their potency
    corecore